[ad_1]
DUBLIN, March 15, 2019 / PRNewswire / – "Global Syndromic Syndrome Diagnostic Markets 2019 to 2023 – Strategies and Trends, Predictions by Syndrome (Respiratory, Sepsis, IG, etc.), by Country, with Market Analysis, Guidance and Customization." the report was added to ResearchAndMarkets.com & # 39; s offer.
Will targeted tests on specific pathogens become obsolete? Will infectious disease screening be transferred to the doctor's office or even to the home?
The syndromic test proves itself on the market. Players report double-digit growth. Reduce costs, improve results and even contribute to the fight against antimicrobial resistance.
Learn more about this market, including issues and prospects. The two key trends in point-of-care testing and molecular diagnostics are merging with spectacular success. This could possibly move most first-line test protocols AND save money at the same time.
The report predicts the size of the market until 2023. In a special section, it badyzes the numbers on how syndromic molecular diagnostics replace traditional methods of testing panel-based infectious diseases.
Topics covered
I. Market Guides
iA. Analysis of the situation
iB. Guide for executives and marketing staff
iC. Guide for investment badysts and management consultants
1. Introduction and definition of the market
1.1 What are syndromic multiplex tests?
1.2 Syndromic tests – the silent revolution of the diagnosis
1.2.1 Syndromic tests – more than just panels.
1.3 Definition of the market
1.3.1 Size of the multiplex market
1.3.2 Size of the panel market
1.3.2 Currency
1.3.3 years
1.4 Methodology
1.4.1 Authors
1.4.2 Sources
1.5 United States Drug Market and Clinical Trials – Perspective
1.5.1 US Health Insurance Expenditures for Clinical Trials
2. Infectious Diseases – Pathogen Guide
2.1 HIV – Human Immunodeficiency Virus (AIDS)
2.1.1 Virology
2.1.1.1 Clbadification
2.1.1.2 Structure and genome
2.1.1.3 Tropism
2.1.1.4 Replication cycle
2.1.1.5 Genetic variability
2.1.2 Diagnosis
2.1.3 Test
2.1.3.1 Antibody tests
2.1.3.2 Point of Service Testing (POCT)
2.1.3.4 Antigen tests
2.1.3.5 Nucleic acid-based tests (NAT)
2.1.3.6 Other tests used in HIV treatment
2.2 HBV – Hepatitis B
2.2.1 Virology
2.2.1.1 Genome
2.2.1.2 Pathogenesis
2.2.1.3 Replication of hepatitis B virus
2.2.1.4 Serotypes and genotypes
2.2.2 Mechanisms
2.2.3 Diagnosis
2.2.4 Analysis of market opportunities
2.3 HCV – Hepatitis C
2.3.1 Taxonomy
2.3.2.1 Structure
2.3.2.2 Genome
2.3.3 Molecular Biology
2.3.4 Replication
2.3.5 Genotypes
2.3.5.1 Clinical importance
2.3.6 Analysis of market opportunities
2.4 HPV – Human Papillomavirus
2.4.1 Virology
2.4.1.1 E6 / E7 Proteins
2.4.1.2 Role in cancer
2.4.1.3 E2 Research
2.4.1.4 Latency period
2.4.1.5 Clearance
2.4.2 Diagnosis
2.4.2.1 Cervical test
2.4.2.2 Oral test
2.4.2.3 Men's test
2.4.2.4 Other tests
2.4.3 Analysis of market opportunities
2.5 Influenza
2.5.1 Virology
2.5.1.1 Types of viruses
2.5.1.2 Influenzaavirus A
2.5.1.3 Influenza virus B
2.5.1.4 Influenzaavirus C
2.5.1.5 Nomenclature of structures, properties and subtypes
2.5.1.6 Replication
2.5.2 Test
2.5.2.1 Advantages / disadvantages of molecular badays
2.5.3 Analysis of market opportunities
2.6 CTGC – Chlamydia / Gonorhea
2.6.1 Gonorrhea
2.6.1.1 Diagnosis
2.6.1.2 Screening
2.6.2 Chlamydia
2.6.2.1 Diagnosis
2.6.2.2 Screening
2.6.3 Test
2.6.3.1 Nucleic Acid Amplification Tests (NAAT).
2.6.3.2 NAAT test performance
2.6.4 Analysis of market opportunities
2.7 Tuberculosis
2.7.1 Mycobacteria
2.7.2 Diagnosis
2.7.2.1 Active tuberculosis
2.7.2.2 Latent tuberculosis
2.7.3 Epidemiology
2.7.4 Molecular diagnostic tests
2.7.5 Analysis of market opportunities
2.8 MRSA – Methicillin-resistant Staphylococcus aureus
2.8.1 Diagnosis
2.8.2 FDA Approved Molecular Tests.
2.8.3 Analysis of market opportunities
2.9 ERV – Enterococci resistant to vancomycin
2.9.1 FDA Approved MDx Tests for VRE
2.9.2 Analysis of market opportunities
3. Overview of the industry
3.1 Participants in the industry
3.1.1 DIV Supplier
3.1.2 Independent, specialized / esoteric laboratory
3.1.3 National / Regional Independent Laboratory
3.1.4 Independent laboratory badysis
3.1.5 National / Regional Public Laboratory
3.1.6 hospital laboratory
3.1.7 Medical laboratory
3.1.8 Control body
3.2 Market segments of clinical laboratories
3.2.1 Segmentation of the traditional market
3.2.2 Concentration and segmentation of the laboratory
3.2.3 Segmentation of the syndromic market
3.3 Structure of the industry
3.3.1 Share of hospital tests
3.3.2 Economies of scale
3.3.2.1 Hospital vs Central Laboratory
3.3.3 Doctor's office laboratories
3.3.4 Physician and PCOT
4. Market Trends
4.1 Driving forces of growth
4.1.1 Speed of diagnosis
4.1.2 Effect of syndromic tests on costs
4.1.3 Point of service advantage
4.1.4 Syndrome test, accuracy and diagnostic risk
4.1.5 Unique visits
4.1.6 Improvement of results
4.2 Factors limiting growth
4.2.1 Lower prices
4.2.2 Infectious diseases are declining but
4.2.3 Well-being hurts.
4.2.4 Economic growth improves standards of living
4.3 Instrumentation and automation
4.3.1 Essential instruments for market share
4.3.2 The shrinking machine
4.3.3 Syndrome test Switch to large instruments?
4.4 Development of diagnostic technology
4.4.1 Comparison of the syndrome and targeted tests
4.4.2 The multiplex paradigm shift
4.4.2 The market for sepsis tests – Bellwether for syndromics
4.4.3 Single visit and antimicrobial resistance
4.4.4 Syndromics promotes the adoption of POCTs
4.4.5 A promising future for PCR?
5. Recent syndromic developments
Recent Developments – Importance and Use of this Section
Importance of these developments
How to use this section
- Akonni Biosystems Submits Multiplex Diagnostic System to FDA
- Ador Diagnosis to receive $ 30 million in the financing of 100 Plex PoC
- SAW Diagnostics Receives Funding for Commercialization of PoC Platform
- QuantuMDx and Molbio announce a protocol of agreement
- Immunexpress wins $ 745 K Contract for rapid sepsis dosing
- Mobidiag ink deals on distribution in Europe and the Middle East
- BIOFIRE FILMARRAY system chosen for the Phase 3 clinical trial
- bioMérieux launches the BIOFIRE FILMARRAY pneumonia panels
- XCR Diagnostics and Luminex Sign License Agreement
- The Palmetto Final LCD refuses the coverage of large breathing panels
- The Karius test will be available in Brazil
- Inflammatix HostDx Fever Test able to quickly distinguish bacterial infections from viral infections
- The Panagene STD kit gets approval
- The GenePOC investment validated by a Medicare decision
- The Startup of Prominex is Up $ 4 million in the A1 series
- Alveo Closes Financing to Create Accessible Diagnostic Devices
- MBio Diagnostics, Inc. Funding Supports Scaling of PoC Testing Platform
- GenePOC launches GenePOC CDiff test in Canada
- Siemens Healthineers Completes Acquisition of Fast Track Diagnostics
- Chembio and FIND to develop a multiplex test at the point of service
- Applied BioCode Receives CE Mark for its Panel of 18 Gastrointestinal Pathogens
- Rapid tests of molecular flu gain ground
- Cepheid Receives FDA Clearance and CLIA Waiver for Xpert Xpress Flu Test
- bioMérieux asks FDA for approval of pneumonia committee
- Mobidiag announces the publication of a qPCR multiplex test for the detection of antibiotic-resistant bacteria
- Fast Track Diagnostics Achieves CE Mark for Real-Time High-Risk HPV PCR Detection
- SEEGENE develops multiplex PCR tests in 4 days
- Seegene enters the US diagnostic market in collaboration with Thermo Fisher Scientific
- Fusion Genomics Developing All Pathogens Diagnosis.
- Anapa Biotech Announces MeltPlex Technology
- First multiplex test for tick-borne diseases
- ArcherDx, MGH continues Qiagen for its anchored multiplex PCR technology
- Akonni Biosystems Forms Chinese Partnership with Righton for Commercialization
- Vela buys Great Basin Scientific
- BARDA price up to $ 30 million to prevent the flu, test for respiratory pathogens
- QIAGEN reaches agreement to acquire STAT-Dx
- GA-EMS receives a diagnostic contract
- Biocartis and Immunexpress Sign Partnership to Fight Sepsis
6. Profiles of the main syndromic test companies
- Abbott Diagnostics (Alere)
- Accelerate diagnostics
- Ador Diagnostics
- Akkoni Biosystems
- Alveo Technologies
- BioCode applied
- Genetic Atlas
- Aus Diagnostics
- BD Diagnostics
- Biocartis
- BioFire Diagnostics
- bioMérieux
- Bio-Rad Laboratories
- Bosch Healthcare Solutions GmbH
- Cepheid
- Curetis
- Diagenode Diagnostics
- Diasorin
- Fusion Genomics
- GenePOC Diagnosis
- GenMark Dx
- Hologic
- Inflammatix
- Invetech
- Janssen Diagnostics
- Karius
- Lexigene
- Luminex
- Mbio Diagnostics
- Mesa Biotech
- Mobidiag
- Nanomix
- Oxford Nanopore
- Panagene
- Primerdesign
- Prominex
- Qiagen (Statdx)
- Quantumdx
- Roche Molecular Diagnostics
- Seegene
- Sensovation
- Siemens Healthineers (Accelerated Diagnosis)
- SkylineDx
- T2 Biosystems
- Thermo Fisher
- Veramarx
- XCR Diagnostics
7. World market size
7.1 Global syndromic market size by country with graphs
7.2 Global syndromic market size by syndrome with graphs
8. World market by syndrome
8.1 Respiratory Syndrome Market
8.1.1 Respiratory syndrome market by country
8.2 Market for gastroenteric syndrome
8.2.1 GI-Enteric market by country with diagram
8.3 Market for blood sepsis syndrome
8.3.1 Blood sepsis market by country with graph
8.4 Meningitis Syndrome Market
8.4.1 Meningitis market by country with graph
8.5 Market for badually transmitted disease syndrome
8.5.1 Sexually transmitted diseases market by country with diagram
8.6 Other Syndrome Market
8.6.1 Other market by country with chart
9. Market test panel – Volumes and price forecasts with MDx action
9.1 Market for respiratory panels
9.2 Gastroenteric panels market
9.3 Sepsis Panel Market
9.4 Meningitis market
9.5 Market for Sexually Transmitted Disease Panels
9.6 Other panel markets
Annexes
I. United States Medicare System: Clinical Laboratory Fee Schedule for 2018 – National and Midpoint Limit
II. FDA approved microbial tests
For more information on this report, visit https://www.researchandmarkets.com/research/hrsb5p/syndromic?w=5.
Research and Markets also offers customized research services that provide targeted, comprehensive and personalized research.
Media contact:
Research and markets
Laura Wood, Main director
[email protected]
For E.S.T office hours, call + 1-917-300-0470
For toll-free calls to the United States and Canada + 1-800-526-8630
For GMT office hours, call + 353-1-416-8900
American fax: 646-607-1907
Fax (outside the United States): + 353-1-481-1716
SOURCE Research and Markets
Related Links
http://www.researchandmarkets.com
Source link
